The Array 2 Intestinal Antigenic Permeability Screen™ is an important initial screening test for patients with multiple chronic GI and neurologic symptoms, suspected food sensitivities, chemical intolerances, or a history of pathogen-induced autoimmune conditions. Array 2 differentiates transcellular versus paracellular intestinal permeability, epithelial barrier dysfunction in the form of actomyosin antibodies, and immune reactivity to lipopolysaccharides (LPS). These types of immune reactivity can lead to imbalances of the gut-brain axis and disruption of the blood-brain barrier.
Clinical Use:
Recommended for Patients Who:
Measures IgG, IgM, and IgA antibodies against endotoxins, structural and tight junction proteins. Detects disturbance in gut flora and endotoxemia, breakdown in tight junctions (occludin, zonulin), and cytoskeletal proteins. Some or all of these contribute to leaky gut to large molecules that challenge the immune system. Leaky gut to large molecules is the gateway to autoimmunity and neuroautoimmunity via blood-brain barriers damaged by endotoxins and other factors. Developed, patented, and published by Aristo Vojdani, PhD, MSc, CLS, known as the father of functional immunology, in 2012, 2013, 2014, 2015, 2017, 2019, 2020, and 2024.